

Curriculum Vitae  
Nasfat Shehadeh, MD

**Practice Address:**

Oncology Specialists of Charlotte  
2711 Randolph Road, Suite 400  
Charlotte, NC 28207  
nshehadeh@oncologycharlotte.com

Oncology Specialists of Charlotte  
7108 Pineville Matthews Road, Suite 102  
Charlotte, NC 28226

**Site Affiliations:**

2021-Present

DJL Clinical Research, PLLC  
10370 Park Road, Suite 200  
Charlotte, NC 28210

**Education:**

2001-2004

Hematology and Oncology Fellowship  
Karmanos Cancer Institute  
Wayne State University  
Detroit Medical Center  
Detroit, Michigan

1994-1997

Internal Medicine Residency  
Wayne State University  
Detroit Medical Center  
Detroit, Michigan

1992-1993

Rotating Internship  
Zarka Teaching Hospital  
Zarka – Jordan

1986-1992

Doctor of Medicine  
Jordan University of Science and Technology  
Irbid - Jordan

**Certifications:**

1992-1993

FMGEMS/ECFMG I & II

1993

FLEX I & II

1997

American Board of Internal Medicine

2004

American Board of Hematology

2004

American Board of Medical Oncology

2010

American Board of Internal Medicine (recertification)

2013-2014

Genetic Cancer Risk Assessment (extensive course) Certificate

2014

American Board of Hematology (recertification)

2014

American Board of Medical Oncology (recertification)

Curriculum Vitae  
**Nasfat Shehadeh, MD**

**Professional Experience:**

Jan 2021-Present	Hematologist and Medical Oncologist Oncology Specialists of Charlotte Charlotte, North Carolina
2015-2020	Attending Hematologist and Medical Oncologist Novant Health Cancer Specialists Charlotte, North Carolina
2009-2015	Medical Director Mercy Cancer Centers Mercy Hematology/Oncology Specialists Attending Hematologist and Medical Oncologist Toledo, Ohio
2007-2009	Attending Hematologist/Oncologist Utah Cancer Specialists Salt Lake City, Utah
2004-2007	Lead Medical Oncologist Head and Neck Cancer and Prostate Cancer Programs University of Minnesota Minneapolis, Minnesota
2003-2004	Chief Hematology and Oncology Fellow Karmanos Cancer Institute Detroit, Michigan
1997-2001	Consultant in Internal Medicine Fairview Red Wing Health Services Red Wing, Minnesota
1993-1994	House Officer Akilah Hospital Amman - Jordan

**Teaching Experience:**

2010-2015	Clinical Assistant Professor Department of Medicine College of Medicine University of Toledo
2009-2015	Teaching Internal Medicine Residents of Mercy St. Vincent Medical Center Teaching Medical Oncology Fellows of University of Toledo Key voluntary faculty member at UT Fellowship Program

Curriculum Vitae  
**Nasfat Shehadeh, MD**

2004-2007                      Assistant Professor of Medicine  
Department of Medicine  
Division of Hematology, Oncology and Transplantation  
University of Minnesota  
Minneapolis, Minnesota

2004-2007                      Teaching and mentoring hematology/oncology fellows  
Mentoring medicine residents, medical students, and physician assistants  
Teaching medical students "Blood Course"  
Supervising fellows' journal club and clinical case conference  
University of Minnesota

**Professional Organizations:**

American Society of Clinical Oncology  
Toledo Academy of Medicine  
National Arab American Medical Association

**Honors and Awards:**

1988                              Dean's Honor List, Jordan University of Science and Technology  
1986-1992                      Scholarship to study medicine for outstanding performance in high school  
2004                              Recognition award for being the chief hematology/oncology fellow  
2009                              Recognition award from Salt Lake Clinic patients for excellent care  
2009                              Consumers' Research Council of America "America's Top Oncologists"  
2009-2012                      Top 50 Smartest Oncologists in the United States (Thesmartestoncologist.com)  
2019-2020                      Charlotte Magazine top Doctors

**Administrative Responsibilities- Medical directorship ( 2009 – 2015 ) :**

PI, Mercy Cancer Centers Clinical Research  
Mercy St. Vincent Hospital Medical Executive Committee (member)  
Mercy Health Partners (MHP) Physicians Governing Council (member)  
Catholic Health Partners (CHP) Formulary Committee (member)  
Mercy St Vincent Transfusion Committee (member)  
Mercy Cancer Network Committee (member)  
Mercy Tumor Board Committee (Chair)  
Mercy Cancer Research Subcommittee (Co-chair)  
Toledo Community Oncology Program (TCOP) Board of Trustees (member)  
Mercy Academic Research and Development Committee (member)

**Administrative Responsibilities- Medical directorship ( 2016– 2020 ) :**

Lead Physician , Novant Health Cancer Specialists – Charlotte  
Member , Cancer Committee  
Co-Lead physician , Hepatobiliary and pancreatic tumor site  
PI , SCOR, Novant Health institution investigator

**Previous Pharmaceutical Speakers' Bureau:**

Imclone  
Bristol-Myers Squibb  
Novartis  
Sanofi-Aventis

**Previous Journal Reviewer:**

Oncology  
International Journal of Cancer Research and Treatment  
Chemotherapy Journal

**Publications:**

Cyclophosphamide Induced Methemoglobinemia. **N Shehadeh**, R Dansey, S Seen & E Abella. Bone Marrow Transplantation (2003)32, 1109-1110

Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: a case report and review of the literature. **N Shehadeh**, G Yoo, J Vernick, J Ensley et al. Am J Otolaryngol 2004; 25:48-53

Enhancement of Ad-p53 Therapy with Docetaxel in Head and Neck Cancer. G Yoo, Piechocki, J Oliver, F Lonardo, L Zumstein, KH Kim, T Shibuya, **N Shehadeh**, J Ensley. Laryngoscope. 2004 Nov; 114(11):1871-9.

Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. **N. J. Shehadeh**, M. Becker, G. Yoo, H.-S. Lin, J. Jacobs, R. Mathog, O. Kucuk, H. Kim, C. Black, J. Ensley Head and Neck. 2006 Dec;28(12):1090-8

Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma. George H. Yoo, MD; Geetha Subramanian, MD; Ramesh Boinpally, PhD; **Nasfat Shehadeh, MD**; Jeffery Oliver, BS; Marie P. Piechocki, PhD; John F. Ensley, MD; Danny Kewson, MD; Ho-Sheng Lin, MD; Terry Y. Shibuya, MD; Lisa Polin, PhD; Ralph Parchment, PhD. Arch Otolaryngol Head Neck Surg. 2005 May;131(5):418-29

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Dudek AZ, Lesniewski-Kmak K, **Shehadeh NJ**, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Br J Cancer. 2009 May 5;100(9):1379-84

**Abstracts:**

Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC)  
Proc Am Soc Clin Oncol 22: page 686, 2003 (abstr 2758)

Oral presentation at the 10th World Conference on Lung Cancer August , 2003Vancouver, Canada. **N. J. Shehadeh**, G. P. Kalemkerian, A. Wozniak, M. Kraut, K. Belzer, D. Ward, C. Hodges, S. M. Gadgeel

Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC).  
ASCO 40th annual meeting 2004, New Orleans , LA ( abstract #7094)  
S. M. Gadgeel, **N. J. Shehadeh**, J. C. Ruckdeschel, R. A. Chaplen, K. Belzer, A. Wozniak

Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO 40th annual meeting 2004, New Orleans , LA (abstract #7102) R. A. Chaplen, G. P. Kalemkerian, A. Wozniak, **N. Shehadeh**, J. C. Ruckdeschel, M. J. Kraut, L. Heilbrun, R. Parchment, S. M. Gadgeel

Phase I study of bortezomib plus cetuximab in patients with tumors expressing epidermal growth factor receptor (EGFR) Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 A. Supplement), 2007: 18143 ; 1/12/2008A. Dudek, P. Gada, K. Mulamalla, **N. Shehadeh**

Curriculum Vitae  
**Nasfat Shehadeh, MD**

Anemia –An Under-recognized Complication from Immunoglobulin Therapy. ACP OH Chapter. **Nasfat Shehadeh, MD**; Owais Idris, MD; Kartik H. Patel, MD; Mushtaq Ashraf, MD. October 25th, 2012

Bortezomib: A Novel Treatment for Severe Refractory Thrombocytopenia Complicating Marginal Cell Lymphoma Hemindermeet Singh MD, **Nasfat Shehadeh MD**, Mercy St. Vincent Medical Center, Toledo, OH ACP, OH Chapter 2013

A rare presentation of prostate metastasis to the lung as an isolated lung mass, Sudhagaran, Anandhi ; **Shehadeh,Nasfat**, Accepted at ACP ,National meeting in Boston April 2015

**Presentations:**

Minnesota Academy of Otolaryngolog, Minneapolis, MN (2004)

Multidisciplinary Cancer Treatment Symposium held at King Hussein Cancer Center, Amman, Jordan (2004)

Annual Masonic Cancer Center Diner Program, Invited Speaker, (Philanthropic support for the University Cancer Center) Minneapolis, MN (2006)

Annual Update and Clinical Learning Day, Invited Speaker, Department of Medicine, Oncology Update (2008), Salt Lake City

43rd Ohio Cancer Registrars Association Annual Meeting (2013)

The Academy of Medicine of Toledo & Lucas County Summer Seminar (2013)

Outcome of Myeloma: optimizing the sequence of treatments including transplant, University of Toledo Symposium, January 2015

**Basic Research:**

Karmanos Cancer Institute / Wayne State University (2003-2004)

Intra tumoral injection of Docetaxel and Ad-p53 in mice

Oral taxanes in animal models to suppress head / neck tumors and prevent second primaries (Dr. George Yoo's R21 grant). Mastered techniques: animal handling, tumor harvesting, paraffin embedding, IHC staining, cell cultures, and data analysis

**Clinical Research:**

**Principal Investigator** - Phase II Pilot Study of TPF (DoceTaxel, CisPlatin, And 5-FU) Induction Chemotherapy Followed By Concurrent Cisplatin And Reduced Dose Radiation In Locally Advanced Head And Neck Cancer (local study 2005- 2007). Investigator initiated trial

This a new concept study trying to reduce dose of radiotherapy in selected head/neck cancer patients ( 2005 concept). Implemented later by Cooperative groups.

**Institution Principal Investigator** - Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone- refractory Prostate Cancer patients 2006

Curriculum Vitae  
Nasfat Shehadeh, MD

**Institution Principal Investigator** - A Randomized, Double Blind, Placebo Controlled, Phase 3 Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Asymptomatic Subjects with Gleason SUM 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas 2004 - 2006

**Principal Investigator** - Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients with Prostate Cancer That Did Not Respond to Hormone Therapy (Phase III CALGB-90401) 2006

**Principal Investigator** - Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy for Prostate Cancer and Bone Metastases (Phase III CALGB -90202) 2005- 2007

**Institution Principal Investigator** - An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (AGS-003-007). Argos Therapeutics Inc. 2013

**Principal Investigator** - A Phase I, Open-Label, Non-Randomized, Multicenter Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients with EGFRm Positive NSCLC whose disease has progressed on EGFR TKI (D5160C00019). Astra Zeneca. 2014

**Institution Principal Investigator** - An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma (E7050-701). Eisai Inc. 2013-2014

**Institution Principal Investigator** - An Open label, Multicenter, Randomized, Phase Ib/II Study of e7050 in Combination with Cetuximab vs. Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck (E7050-702). Eisai Inc. 2012-2014

**Institution Principal Investigator** - A phase II multicenter randomized controlled open label study of bendamustine plus rituximab with or without navitoclax in patients with relapsed diffuse large b cell lymphoma (GP27814). Genentech, Inc. 2011-2012

**Institution Principal Investigator** - An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Saefy and Efficacy of Ramucirumab (IMC-1121B) in Combination with Eribulin versus Eribulin Monotherapy in Unresectable, Locally-advanced or Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane Therapy (14TIEJVCD). ImClone Systems Corp. 2012-2013

**Institution Principal Investigator** - A randomized, double blind phase 3 study of the JAK1/2 inhibitor, ruxolitinib or placebo in combination with Capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first line chemotherapy (INCB 18424-362). Incyte Corporation. 2014

**Institution Principal Investigator** - Prospective non interventional study of disease progression and treatment of patients with polycythemia vera in United States academic or community clinical practices (REVEAL) (INCB-MA-PV-401). Incyte Corporation. 2014

Curriculum Vitae  
**Nasfat Shehadeh, MD**

**Institution Principal Investigator** - A Phase 1b/2 Randomized Study of MEDI-573 in Combination with and Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC) (CD-ON-MEDI-573-1030). MedImmune LLC. 2012-2014

**Institution Principal Investigator** - A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer (CD-ON-MEDI-575-1031). MedImmune LLC. 2012-2014

**Institution Principal Investigator** - An open label, Phase 1/2 study of MEDI-551, A Humanized Monoclonal Antibody Directed against CD19, in adult subjects with relapsed or refractory advanced B-cell Malignancies. (MLCP204). MedImmune LLC. 2014-Present

**Institution Principal Investigator** - An Open-Label, Dose-Escalation, Phase 1,2 Study of the Oral Formulation of MLN9708 Administered Twice-Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment (C16008). Millennium Pharmaceuticals, Inc. 2012-2015

**Institution Principal Investigator** - A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter Trial of Allisertib (MLN8237) or Investigators Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (C14012). Millennium Pharmaceuticals Inc. 2012-2014

**Institution Principal Investigator** - A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (C16014). Millennium Pharmaceuticals Inc. 2013-Present

**Institution Principal Investigator** - A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects with Chemorefractory Metastatic Colorectal Cancer (MORAb-004). Morphotek, Inc. 2012-2013

**Institution Principal Investigator** - Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy (REO 018). Oncolytics Biotech. 2011-2014

**Institution Sub-Investigator** - Randomized Phase II Study of Bevacizumab/mFOLFFOX6 vs. Bevacizumab/FOLFIRI with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer (MAVERICC) (MLN25710) (2014)

**Institution Sub-Investigator** - Randomized Multicenter Study Comparing Pixantrone + Ritizimab with Gemcitabine and Rituximab in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma who have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant (PIX306). 2012-2014

**Institution Sub-Investigator** - Prospective, Randomized, Multi-Center, Multinational, Double-blind Placebo Controlled Comparison of Chemotherapy Plus Trastuzumab and Placebo Given for a Total of One Year vs. Chemotherapy Plus Trastuzumab and Pertuzumab given for a Total of One Year as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer (BO25126). 2013-2014

Curriculum Vitae  
Nasfat Shehadeh, MD

**Sub- Investigator** – Novocure: LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure

**Sub- Investigator** – GSK: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer

**Principal Investigator** – Fibrogen: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)

**Sub-Investigator** – UBC: Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

**Sub-Investigator** – BMS/Labcorp: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies


**Principal Investigator** – Myovant: A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®

**Sub-Investigator** – Regeneron: A Phase 1/2 Study Of Cemiplimab (Anti-PD-1 Antibody) In Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1  $\geq 50\%$

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.



Signature



Date